Bicyclic substituted pyrimidine compounds

摘要

Disclosed are bicyclic group substituted pyrimidine compounds, pharmaceutical acceptable salts thereof or stereoisomers thereof. Also disclosed are preparation methods, pharmaceutical formulations, and pharmaceutical compositions of the compounds, and use of the compounds, pharmaceutical formulations, and pharmaceutical compositions for preparing a medicament for treating and/or preventing sexual dysfunction diseases and diseases with lower urinary tract symptoms.

主权项

1. A compound of Formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof:wherein
R1 is selected from the group consisting of saturated 6 to 7 membered N-containing fused heterocyclyl, 7 to 12 membered N-containing spiro heterocyclyl and 7 to 12 membered N-containing bridged heterocyclyl; each attached to pyrimidyl via nitrogen and optionally substituted with a substituent selected from the group consisting of halogen, cyano, amino, hydroxyl, C1-6 alkyl, halo C1-6 alkyl, hydroxyl C1-6 alkyl, C1-6 alkoxyl, C1-6 alkylcarbonyl and C1-6 alkoxylcarbonyl, wherein the number of the substituent is 1 to 4; R2 is selected from the group consisting of hydrogen, hydroxyl, amino, cyano, C1-6 alkylamino, di(C1-6 alkyl)amino,C1-6 alkyl, halo C1-6 alkyl, hydroxyl C1-6 alkyl and C1-6 alkoxyl; R3 and R4 are each independently selected from hydrogen and -M-R7, M is selected from a single bond and C1-6 alkylene optionally substituted with substituent L1, R7 is selected from 3 to 14 membered cyclic group optionally substituted with substituent L2, or R3 and R4 together with nitrogen attached to R3 and R4 form a 5 to 6 membered N-containing heterocyclyl optionally substituted with substituent L3, said substituents L1, L2 and L3 are selected from the group consisting of halogen, hydroxyl, cyano, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, oxo, C1-6 alkyl, hydroxyl C1-6 alkyl, halo C1-6 alkyl, C1-6 alkoxyl, C1-6 alkylcarbonyl, C1-6 alkylsulfonyl and di(C1-6 alkyl)phosphino, wherein the number of the substituent is 1 to 4; R5 and R6 are each independently selected from hydrogen and -Q-R8, Q is selected from a single bond and C1-6 alkylene optionally substituted with substituent L4, R8 is selected from the group consisting of 6 to 14 membered aryls, 5 to 7 membered monocyclic heterocyclyl, 8 to 9 membered fused cyclyl and 8 to 9 membered fused heterocyclyl; each optionally substituted with substituent L5, said substituents L4 and L5 are selected from the group consisting of halogen, hydroxyl, C1-6 alkyl, halo C1-6 alkyl, carboxyl C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxyl, halo C1-6 alkoxyl, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, cyano, nitro, C1-6 alkylcarbonyl, sulfonyl amino and C1-6 alkyl sulfonyl amino, wherein the number of the substituent is 1 to 4.